PTK2 and meningioma: Early results of FAK inhibition in recurrent or progressive meningioma have shown a PFS-6 of 83.3% and a median PFS of 12.8 months in WHO grade 1 meningioma, whereas PFS-6 was 33.3% and median PFS 3.7 months in WHO grade 2–3 meningioma.